Comparing testing methods for type of cancers in 2015

IVDNewsTM captures data from around the world on methods used to detect, monitor and provide prognosis on a variety of cancers – both somatic driven and germ cell or genetic based. As the methods or technology change there is always an adoption phase and medical practice phase driven by regional dynamics of cancer (e.g., incidence, government funding, private insurance).

The table below is a comparison of the methods used to identify two groups of cancers and those cancers that are under investigation using the newer miRNA methods. The comparison is made based on the number of publications captured in IVDNewsTM for 1H 2015 and 2H 2015. Analysis of the publications can identify a number of key marketing parameters, some of the parameters include:

  • name and location of facilities involved with specific biomarkers (geographic segmentation)
  • trends in testing methods
  • KOL’s by country or region
  • sales leads by region or country
  • differences in medical practice by regions and
  • differences in clinical issues by regions

Groups are divided in IVDNewsTM with Topics as follows:
Group 1 – Prostate, Lung, Breast, Colon, Cervical, and Ovarian cancer
Group 2 – Thyroid, Liver, Bladder, Renal, Melanoma, Pancreatic, Kidney, other minor cancers
Group 3 – Special category for all solid tumor cancers using miRNA methods

Period Method

Journals

Abstracts

Press releases

Total #

1H 2015          
Group 1

 

Immuno

Molecular

107

201

98

335

23

88

228

624

Group 2 Immuno

Molecular

70

97

70

160

11

45

151

302

Group 3 Only Molecular

103

66

6

175

           
2H 2015          
Group 1 Immuno

Molecular

111

248

58

282

23

114

192

644

Group 2 Immuno

Molecular

57

87

74

124

10

32

141

243

Group 3 Only Molecular

95

46

6

147

An example of using the data is comparing methods by types of cancers in Asiatic Countries versus Germany. Journals and abstracts invariably identify the author, institutions and location as well as email contacts in a number of cases.

For cancers Thyroid, Liver, Bladder, Renal, Melanoma, Kidney and Pancreatic

Total 2015

Method

Germany

China

Japan

Korea

Immuno

9

47

25

13

Molecular

18

24

27

21

Even though the number of molecular publications for these cancers in 2015 was significantly larger than immuno methods (545 to 292), the use of immuno methods was still larger than molecular methods (85 to 72) in the 3 Asian countries. When the largest EU Country, Germany, is compared to the Asian countries the use of molecular methods (18) is not significantly less than any of the Asian countries given the huge difference in population. However, when comparing immuno methods there is a significant difference as immuno is still the dominant technology for the Asian countries.

These data would point that for the near term the market for immunoassays for these cancers will be in the Asian countries.

Consider using the IVDNewsTM data base via the Data Analysis Reports (DARs) to obtain a variety of market and technology metrics to support R&D, Business Development and Marketing strategies and plans.

Leave A Comment

You must be logged in to post a comment.